Blood levels of two proteins in rheumatoid arthritis with lung disease
Measures two blood proteins in adults with rheumatoid arthritis and lung scarring.
Plain-language title generated from the registry record
Registry title: "Matrix Metalloproteinases 7 and 9 in Rheumatoid Arthritis Patients With Interstitial Lung Disease"
Key facts
- Where
- Asyut, EgyptSee the site
Where in Egypt
- Assuit universityAsyut, EgyptNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Assiut University
- Trial code
- NCT07173582
- Record updated
- 15 September 2025
- Original description
This case control study will be done at Rheumatology Department, Assiut University Hospital. It will include RA patients fulfilling the American College of Rheumatology and European League against Rheumatism (ACR / EULAR) 2010 classification criteria.Read full original descriptionShow less
"Matrix Metalloproteinases 7 and 9 in Rheumatoid Arthritis Patients With Interstitial Lung Disease and Its Relation to Disease Activity"
This case control study will be done at Rheumatology Department, Assiut University Hospital. It will include RA patients fulfilling the American College of Rheumatology and European League against Rheumatism (ACR / EULAR) 2010 classification criteria.
Aim of the study
* To assess the matrix metalloproteinase 7 and 9 (MMP7,9) as a screening tool for interstitial lung disease in rheumatoid arthritis patients and to assess for correlation with RA-disease activity. * To investigate whether certain MMPs could be potential biomarkers reflecting the lung fibrotic process in RA patients. * To assess the capillaroscopy changes in RA and RA-ILD. * To detect correlation between MMPs and capillaroscopic changes in RA patients. This case control study will be done at Rheumatology Department, Assiut University Hospital. It will include RA patients fulfilling the American College of Rheumatology and European League against Rheumatism (ACR / EULAR) 2010 classification criteria.
The patients will be divided into 3 groups:
Group (1): RA patients with ILD. Group (2): RA patients without ILD Group (3): Healthy controls
All patients will be subjected to:
A- Complete medical history:
Detailed medical history will be taken including demographic data (age, sex, disease duration, morning stiffness, joint involvement, smoking, habits of medical importance), articular and extra articular manifestations. Detailed respiratory manifestations as (dyspnea, cough, chest wheeze, others)
B- Clinical examination:
* General and local rheumatological examination. * Local chest examination (inspection, palpation, percussion, auscultation). * Assessment of RA disease activity using DAS 28 ESR. Score interpretation <2.6 suggests disease remission. 2.6-3.2 suggests low disease activity 3.2-5.1 suggests moderate disease activity >5.1 suggest high disease activity
C- Laboratory investigations:
Peripheral venous blood samples for CBC, C-reactive protein, erythrocyte sedimentation rate, antibody status.
D- Radiology and PFT:
PFTs and HRCT chest patterns will be done for patients.
E- MMP measurement:
Serum samples will be collected at the time of registry enrollment, MMP 7 and 9 concentrations will be measured using enzyme-linked immunosorbent assas.
This ELISA kit uses the Sandwich-ELISA principle.
Inclusion: 1- Age >18. 2- RA diagnosis according (ACR / EULAR) 2010.
Exclusion: Other connective tissue diseases (systemic sclerosis, systemic Lupus and Mixed connective tissue disease); Malignancy; Congestive heart failure; Age <18 years; Another chest presentation; Patient refuse; Patients with recent nail trauma; Patients with heavy manual activities; Poor nailfold hygiene; Individuals unable to cooperate during the nailfold capillaroscopic examination.